Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study.

Ferrannini E, Baldi S, Frías JP, Guja C, Hardy E, Repetto E, Jabbour SA, DeFronzo RA

Diabetes, obesity & metabolism8 Oct 2019Cited by 8 (Europe PMC)

PMID31469220DOI10.1111/dom.13870PepBankPUB-31469220

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialMechanism
In patients with diabetes, fasting insulin-to-glucagon ratio increased only with exenatide plus placebo.
In plain wordsIn patients with diabetes, fasting insulin-to-glucagon ratio increased only with exenatide plus placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseFasting insulin-to-glucagon ratio
Study
n: not reported in source
Comparator
Baseline
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
The fasting insulin-to-glucagon molar ratio (I/Glg) increased with EQW + Plb only;
1 context sentence(design, population, supporting numbers)
Summary · context
In DURATION-8, the combination of once-weekly exenatide (EQW) + 10 mg dapagliflozin (Dapa) in patients with type 2 diabetes poorly controlled with metformin-reduced HbA1c levels and body weight (at weeks 28 and 52) was compared with EQW + placebo (Plb) or Dapa + Plb.
Report a problemFND-3146922001
02HumanRandomized controlled trialMechanism
In patients with diabetes, postprandial insulin-to-glucagon ratio increased in all groups, but more with exenatide plus placebo.
In plain wordsIn patients with diabetes, post-meal insulin-to-glucagon ratio increased in all groups, but more with exenatide plus placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreasePostprandial insulin-to-glucagon ratio
Study
n: not reported in source
Comparator
Other treatment groups
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
postprandial I/Glg increased in all groups but significantly more with EQW + Plb.
1 context sentence(design, population, supporting numbers)
Summary · context
In DURATION-8, the combination of once-weekly exenatide (EQW) + 10 mg dapagliflozin (Dapa) in patients with type 2 diabetes poorly controlled with metformin-reduced HbA1c levels and body weight (at weeks 28 and 52) was compared with EQW + placebo (Plb) or Dapa + Plb.
Report a problemFND-3146922002
03HumanRandomized controlled trialMechanism
In patients with diabetes, beta-hydroxybutyrate decreased with exenatide plus placebo, while dapagliflozin produced larger increases and combination treatment intermediate changes.
In plain wordsIn patients with diabetes, beta-hydroxybutyrate decreased with exenatide plus placebo, unlike dapagliflozin, while combination treatment produced intermediate changes.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBeta-hydroxybutyrate
Study
n: not reported in source
Comparator
Baseline
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
β-OH, FFA, and glycerol concentrations showed a parallel response: larger increments with Dapa + Plb, larger decrements with EQW + Plb, and intermediate changes with EQW + Dapa.
1 context sentence(design, population, supporting numbers)
Summary · context
In DURATION-8, the combination of once-weekly exenatide (EQW) + 10 mg dapagliflozin (Dapa) in patients with type 2 diabetes poorly controlled with metformin-reduced HbA1c levels and body weight (at weeks 28 and 52) was compared with EQW + placebo (Plb) or Dapa + Plb.
Report a problemFND-3146922003
04HumanRandomized controlled trialMechanism
In patients with diabetes, free fatty acids decreased with exenatide plus placebo, while dapagliflozin produced larger increases and combination treatment intermediate changes.
In plain wordsIn patients with diabetes, free fatty acids decreased with exenatide plus placebo, unlike dapagliflozin, while combination treatment produced intermediate changes.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseFree fatty acids
Study
n: not reported in source
Comparator
Baseline
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
β-OH, FFA, and glycerol concentrations showed a parallel response: larger increments with Dapa + Plb, larger decrements with EQW + Plb, and intermediate changes with EQW + Dapa.
1 context sentence(design, population, supporting numbers)
Summary · context
In DURATION-8, the combination of once-weekly exenatide (EQW) + 10 mg dapagliflozin (Dapa) in patients with type 2 diabetes poorly controlled with metformin-reduced HbA1c levels and body weight (at weeks 28 and 52) was compared with EQW + placebo (Plb) or Dapa + Plb.
Report a problemFND-3146922004
05HumanRandomized controlled trialMechanism
In patients with diabetes, glycerol decreased with exenatide plus placebo, while dapagliflozin produced larger increases and combination treatment intermediate changes.
In plain wordsIn patients with diabetes, glycerol decreased with exenatide plus placebo, unlike dapagliflozin, while combination treatment produced intermediate changes.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGlycerol
Study
n: not reported in source
Comparator
Baseline
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
β-OH, FFA, and glycerol concentrations showed a parallel response: larger increments with Dapa + Plb, larger decrements with EQW + Plb, and intermediate changes with EQW + Dapa.
1 context sentence(design, population, supporting numbers)
Summary · context
In DURATION-8, the combination of once-weekly exenatide (EQW) + 10 mg dapagliflozin (Dapa) in patients with type 2 diabetes poorly controlled with metformin-reduced HbA1c levels and body weight (at weeks 28 and 52) was compared with EQW + placebo (Plb) or Dapa + Plb.
Report a problemFND-3146922005
06HumanRandomized controlled trialMechanism
In patients with diabetes, adding exenatide to dapagliflozin produced lower beta-hydroxybutyrate changes than dapagliflozin plus placebo.
In plain wordsIn patients with diabetes, adding exenatide to dapagliflozin lowered beta-hydroxybutyrate changes compared with dapagliflozin plus placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseCombination beta-hydroxybutyrate change
Study
n: not reported in source
Comparator
Dapagliflozin plus placebo
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
β-OH, FFA, and glycerol concentrations showed a parallel response: larger increments with Dapa + Plb, larger decrements with EQW + Plb, and intermediate changes with EQW + Dapa.
1 context sentence(design, population, supporting numbers)
Summary · context
In DURATION-8, the combination of once-weekly exenatide (EQW) + 10 mg dapagliflozin (Dapa) in patients with type 2 diabetes poorly controlled with metformin-reduced HbA1c levels and body weight (at weeks 28 and 52) was compared with EQW + placebo (Plb) or Dapa + Plb.
Report a problemFND-3146922012
07HumanRandomized controlled trialMechanism
In patients with diabetes, adding exenatide to dapagliflozin produced lower free fatty acid changes than dapagliflozin plus placebo.
In plain wordsIn patients with diabetes, adding exenatide to dapagliflozin lowered free fatty acid changes compared with dapagliflozin plus placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseCombination free fatty acid change
Study
n: not reported in source
Comparator
Dapagliflozin plus placebo
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
β-OH, FFA, and glycerol concentrations showed a parallel response: larger increments with Dapa + Plb, larger decrements with EQW + Plb, and intermediate changes with EQW + Dapa.
1 context sentence(design, population, supporting numbers)
Summary · context
In DURATION-8, the combination of once-weekly exenatide (EQW) + 10 mg dapagliflozin (Dapa) in patients with type 2 diabetes poorly controlled with metformin-reduced HbA1c levels and body weight (at weeks 28 and 52) was compared with EQW + placebo (Plb) or Dapa + Plb.
Report a problemFND-3146922013
08HumanRandomized controlled trialMechanism
In patients with diabetes, adding exenatide to dapagliflozin produced lower glycerol changes than dapagliflozin plus placebo.
In plain wordsIn patients with diabetes, adding exenatide to dapagliflozin lowered glycerol changes compared with dapagliflozin plus placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseCombination glycerol change
Study
n: not reported in source
Comparator
Dapagliflozin plus placebo
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
β-OH, FFA, and glycerol concentrations showed a parallel response: larger increments with Dapa + Plb, larger decrements with EQW + Plb, and intermediate changes with EQW + Dapa.
1 context sentence(design, population, supporting numbers)
Summary · context
In DURATION-8, the combination of once-weekly exenatide (EQW) + 10 mg dapagliflozin (Dapa) in patients with type 2 diabetes poorly controlled with metformin-reduced HbA1c levels and body weight (at weeks 28 and 52) was compared with EQW + placebo (Plb) or Dapa + Plb.
Report a problemFND-3146922014
09HumanRandomized controlled trialMechanism
In patients with diabetes, haematocrit increased only in the dapagliflozin group, with no increase reported for exenatide.
In plain wordsIn patients with diabetes, haematocrit increased only with dapagliflozin, with no increase reported for exenatide.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeHaematocrit
Study
n: not reported in source
Comparator
Baseline
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Haematocrit increased only in the Dapa group.
1 context sentence(design, population, supporting numbers)
Summary · context
In DURATION-8, the combination of once-weekly exenatide (EQW) + 10 mg dapagliflozin (Dapa) in patients with type 2 diabetes poorly controlled with metformin-reduced HbA1c levels and body weight (at weeks 28 and 52) was compared with EQW + placebo (Plb) or Dapa + Plb.
Report a problemFND-3146922015

Studies that did not test the peptide alone4

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

10HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialMechanism
In patients with diabetes, postprandial insulin-to-glucagon ratio increased with exenatide plus dapagliflozin, as in every group.
In plain wordsIn patients with diabetes, post-meal insulin-to-glucagon ratio increased with exenatide plus dapagliflozin, as in every group.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseCombination postprandial insulin-to-glucagon ratio
Study
n: not reported in source
Comparator
Baseline
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Source sentences
Summary
The fasting insulin-to-glucagon molar ratio (I/Glg) increased with EQW + Plb only; postprandial I/Glg increased in all groups but significantly more with EQW + Plb.
1 context sentence(design, population, supporting numbers)
Summary · context
In DURATION-8, the combination of once-weekly exenatide (EQW) + 10 mg dapagliflozin (Dapa) in patients with type 2 diabetes poorly controlled with metformin-reduced HbA1c levels and body weight (at weeks 28 and 52) was compared with EQW + placebo (Plb) or Dapa + Plb.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3146922011
11HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialMechanism
In patients with diabetes, exenatide plus dapagliflozin produced higher beta-hydroxybutyrate changes than exenatide plus placebo.
In plain wordsIn patients with diabetes, exenatide plus dapagliflozin produced higher beta-hydroxybutyrate changes than exenatide plus placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseCombination beta-hydroxybutyrate change versus exenatide
Study
n: not reported in source
Comparator
Exenatide plus placebo
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Source sentences
Summary
β-OH, FFA, and glycerol concentrations showed a parallel response: larger increments with Dapa + Plb, larger decrements with EQW + Plb, and intermediate changes with EQW + Dapa.
1 context sentence(design, population, supporting numbers)
Summary · context
In DURATION-8, the combination of once-weekly exenatide (EQW) + 10 mg dapagliflozin (Dapa) in patients with type 2 diabetes poorly controlled with metformin-reduced HbA1c levels and body weight (at weeks 28 and 52) was compared with EQW + placebo (Plb) or Dapa + Plb.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3146922016
12HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialMechanism
In patients with diabetes, exenatide plus dapagliflozin produced higher free fatty acid changes than exenatide plus placebo.
In plain wordsIn patients with diabetes, exenatide plus dapagliflozin produced higher free fatty acid changes than exenatide plus placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseCombination free fatty acid change versus exenatide
Study
n: not reported in source
Comparator
Exenatide plus placebo
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Source sentences
Summary
β-OH, FFA, and glycerol concentrations showed a parallel response: larger increments with Dapa + Plb, larger decrements with EQW + Plb, and intermediate changes with EQW + Dapa.
1 context sentence(design, population, supporting numbers)
Summary · context
In DURATION-8, the combination of once-weekly exenatide (EQW) + 10 mg dapagliflozin (Dapa) in patients with type 2 diabetes poorly controlled with metformin-reduced HbA1c levels and body weight (at weeks 28 and 52) was compared with EQW + placebo (Plb) or Dapa + Plb.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3146922017
13HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialMechanism
In patients with diabetes, exenatide plus dapagliflozin produced higher glycerol changes than exenatide plus placebo.
In plain wordsIn patients with diabetes, exenatide plus dapagliflozin produced higher glycerol changes than exenatide plus placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseCombination glycerol change versus exenatide
Study
n: not reported in source
Comparator
Exenatide plus placebo
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Source sentences
Summary
β-OH, FFA, and glycerol concentrations showed a parallel response: larger increments with Dapa + Plb, larger decrements with EQW + Plb, and intermediate changes with EQW + Dapa.
1 context sentence(design, population, supporting numbers)
Summary · context
In DURATION-8, the combination of once-weekly exenatide (EQW) + 10 mg dapagliflozin (Dapa) in patients with type 2 diabetes poorly controlled with metformin-reduced HbA1c levels and body weight (at weeks 28 and 52) was compared with EQW + placebo (Plb) or Dapa + Plb.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3146922018

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.